期刊文献+

抗分枝杆菌药物研究最新进展 被引量:3

Advance in study of new antimycobacterial drugs
原文传递
导出
摘要 随着人类免疫缺陷病毒(HIV)感染和艾滋病(AIDS)的流行,全球结核病和非结核分枝杆菌(NTM)病呈增多趋势,严重威胁着人类的生命和健康。由于耐药或耐多药结核分枝杆菌和NTM对大多常用的抗分枝杆菌药物均不敏感,因此,给临床治疗带来了极大的困难。本文就抗分枝杆菌药物的最新研究进展做一介绍。 In recent years, the incidences of tuberculosis and non-tuberculous mycobacterial diseases have been increasing substantially on a world wild along with HIV and AIDS epidemics, and has been seriously threatening man's life and health. Because of drug or multidrug-resistant strains of Mycobacterium tuberculosis and non-tuberculous mycobacterium unsusceptible to most of the conventional antimycobacterial drugs, serious problems bring out for clinical treatment. In this article, we reviewed the development of new antimycobacterial drugs.
出处 《国际呼吸杂志》 2007年第5期350-354,共5页 International Journal of Respiration
关键词 结核病 非结核分枝杆菌病 分枝杆菌属 药物治疗 Tuberculosis Non-tuberculous mycobacterial diseases Mycobacteria Drug therapy
  • 相关文献

参考文献40

  • 1Senol G, Erbaycu A, Ozsoz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother, 2005,17 : 380-384,
  • 2Rodriguez JC, Cebrian L, Ruiz M, et al. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis. Chemotherapy, 2005,51 : 76-79.
  • 3Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis, 2002,6 : 164-165.
  • 4Lenaerts AM, Chase SE, Cynamon MH. Evaluation of rifalazil in a combination treatmant regimen as an alternative to isoniazidrifampin therapy in a mouse tuberculosis model. Antimicrob Agents Chemother , 2000 , 44 : 3167- 3168.
  • 5Dietze R, Teixeira L, Rocha LM, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.Antimicrob Agents Chemother,2001,45 1972-1976.
  • 6Chan CY, Au-Yeang C, Yew WW, et al. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother,2004,48:340-343.
  • 7Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1, 200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med, 2004, 169:1191-1197.
  • 8Sirgel FA, Fourie PB, Donald PR, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.Am J Respir Crit Care Med,2005,172:128-135.
  • 9American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med, 2003,167 : 603-662.
  • 10唐神结,肖和平.耐多药结核病的综合治疗[J].中华结核和呼吸杂志,2003,26(11):715-718. 被引量:65

二级参考文献15

共引文献64

同被引文献29

  • 1高春荣,袁东运,徐立江.含阿米卡星及左氧氟沙星方案治疗耐多药肺结核近期疗效观察[J].中国防痨杂志,2004,26(3):165-167. 被引量:14
  • 2谭守勇,黎燕琼.氟喹诺酮类药物在耐多药结核病治疗中的应用[J].中国防痨杂志,2005,27(4):267-270. 被引量:30
  • 3GRIFFITH DE, AKSAMIT T, BROWN - ELLIOTT BA, et al. An official ATS/IDSA statement : diagnosis, treatment, and preven- tion of non - tuberculous mycobacterial diseases [ J ]. Am J Respir Crit Care Med,2007,175(4) :367 -416.
  • 4WHO. Treatment of tuberculosis: guidelines for national programmes[ S]. 3rded. Geneva: World Health Organizati on, 2003.
  • 5KOH WJ,JEON K,IZE N Y,et al. Clinical significance of differentiation of M,lcohactel3nnl massiliense from Mycobacterium abscessus [ J ]. Am J Respir Crit Care Med ,2011,183:405 - 410.
  • 6CONDOS R, HADGIANGELIS N, LEIBERT E, et al. Case series report of a linezolid - containing regim en for extensively drug - re- sistant tuberculosis[J]. Chest, 2008, 134 ( 1 ) :187 - 192.
  • 7KOHWJ, KWON O J, GWAKH, etal. Daily 300 mgdoseof linezolid for the treatment of in tractable multidrug - resistant and extensively drugresistant tuberculosis [ J ]. J Antimicrob Chemother, 2009,64(2) :388 -391.
  • 8NAM H S, KOH W J, KW ON OJ,et al. Daily hal - f dose lin- ezolid for the treatment of intractable multi drug - resistant tuberculosis [ J ]. Int J Antimicrub Agents,2009,33 (1) : 92 -93.
  • 9LEE M, LEE J, CARROLL MW, et al. Linezolid for Treatment of Chronic Extensively Drug - Resistant Tuberculosis [ J ]. The new england journal of medicine,2012,367(16) :1508 - 1518.
  • 10何霞,蔡杏珊,刘志辉.非结核分枝杆菌分离与致病的相关性研究[J].国际医药卫生导报,2008,14(21):13-14. 被引量:10

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部